Stanford University CogT Lab
Palo Alto, California, 94304-0000, United States
Location status: Recruiting
NCT Number: NCT07130669
How to ensure adherence to computerized cognitive training in unsupervised circumstances (e.g., at-home, self-administered) in older adults at risk for Alzheimer's disease (AD) or AD related dementia (AD/ADRD) is understudied. The objective of the R33 study is to test a novel facial expression-based personalization engine (FPE) for monitoring and modulating real-time effective engagement, with an ultimate goal of enhancing long-term adherence in unsupervised cognitive training in older adults at risk for AD/ADRD. Here, Effective engagement is defined as the extent to which someone is actively engaged and performing with significant attention and enjoyment while training, addressing a balance between adherence and cognitive gains/plasticity from the training. Based on previous work, the hypotheses include that (1) mental fatigue revealed in facial expressions will reflect a trainee's degree of effective engagement, which can be modified by modulating task novelty; (2) the proposed FPE will ensure the effective engagement in cognitive training by monitoring trainee facial expressions and modulating training in response, promoting the trainee's long-term adherence to the training and cognitive plasticity. A Stage II intervention efficacy study will be conducted to compare effective engagement and adherence in unsupervised cognitive training between training programs with vs. without FPE in older adults at risk for AD/ADRD. The proposed FPE may assist in monitoring and improving effective engagement and adherence in older adults with unsupervised cognitive training. In the current application, FPE in a cognitive training program called speed of processing training will be tested. However, such FPE may be embedded to any computerized cognitive training in future studies to help address adherence related issues.
Interested in participating?
Request Info60 year–89 year
All sexes
Interventional
Phase 1 / Phase 2
Palo Alto, California, 94304-0000, United States
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
computerized cognitive training with a closed-loop human machine interface that monitor facial expression as engagement status of the person
traditional computerized cognitive training
Other names: traditional computerized cognitive training
Time frame: up to 8 weeks, throughout the intervention sessions
facial expression+ECG
Time frame: up to 8 weeks, throughout the intervention sessions
Time frame: up to 8 weeks, throughout the intervention sessions
likert scale, 6 items, summarized as 0-10 points
Time frame: baseline assessment at week 0, post-intervention assessment at week 7, followup assessment at week 13
BVMT-R delayed recall t score
Time frame: baseline assessment at week 0, post-intervention assessment at week 7, followup assessment at week 13
EXAMINER composite score
Contact information is provided by the study sponsor or research team.
Stanford University
Other
A Facial Expression-based Personalization Engine (FPE) for Monitoring and Modulating Real-time Effective Engagement in Cognitive Training in Older Adults at Risk for AD/ADRD (CogT FACE Study Phase II)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07731334
Brain Diseases, Central Nervous System Diseases
Florence, FI, Italy
View Trial DetailsNCT07366346
Brain Diseases, Central Nervous System Diseases
Gainesville, Florida, United States
View Trial DetailsNCT07580703
AD - Alzheimer's Disease, Alzheimer Disease
Beijing, Beijing Municipality, China
View Trial DetailsNCT06633978
Aging, MCI
San Francisco, California, United States
View Trial Details